Signal Scanner · HEALTH, LIFE SCIENCES & CARE SYSTEMS · 13 September 2026

America's Nuclear Regulator Treats Oncology Capacity as a Licensing Problem and Deregulates the Authorised User

Radioligand cancer therapy is constrained less by isotope supply than by shielded rooms and by the legal definition of who may administer the dose. The US response, proposed on 27 July 2026, is to loosen that definition. Exposed: oncology networks, radiopharmaceutical developers, payers, hospital capital planning and life-sciences investors.

The consensus story about radioligand therapy is a supply story. Demand for targeted radiopharmaceuticals is rising, isotope production is the choke point, and the industry's answer is actinium and lutetium capacity plus contract manufacturing. Underneath that, a different ceiling binds. Treatment requires a shielded room, a hot lab, radioactive-waste handling and, decisively, a physician who meets the legal definition of an authorised user, all of which sit under nuclear regulation rather than health regulation. On 27 July the US Nuclear Regulatory Commission proposed to delete the prescriptive training hours behind that definition and to remove the licence amendment needed to add a diagnostic authorised user. Capacity is being expanded by redefining who is lawfully qualified.

Signal Identification

A regulatory pivot with a measurement problem behind it. A nuclear safety regulator has become a rate-limiter on oncology capacity, and the lever now being pulled is the qualification standard rather than the capital stock. The exposure is commercial and legal at once: forecasts are anchored on eligible patients while delivery is bounded by licensed rooms and authorised users, and assurance of who is qualified moves from prior approval to retrospective inspection.

Time horizon: 1-9 years (NRC proposed rule 27 July 2026, comments closed 10 September 2026; CY 2027 Medicare payment year from January 2027; European eligible pool modelled to 2035)
capacity binds2026202720302031to 2035
Plausibility band: Medium–High
LowMediumHigh
Geographic / Jurisdictional Scope: Primary: the United States, where the NRC and the Agreement States license medical use and Medicare sets the price. Spillover: the EU-27 and the EU-4, where the eligible pool is modelled to grow fastest, and lower- and middle-income systems where the delivery estate is thinnest.
PrimaryUnited States
SpilloverEU-27 and EU-4LMIC health systems
Sectors exposed:
Hospital nuclear medicine and oncology service linesRadiopharmaceutical developers and CDMOsHealth-system capital planningMedical physics and nuclear medicine workforceMedicare and commercial payersRadiology and radiation oncology professional bodiesLife-sciences investors

What's Changing

The qualification standard is the instrument. The NRC proposes to remove the prescriptive classroom, laboratory and work-experience hour requirements across eight sections of 10 CFR Part 35 for physicians who completed a residency in a specialty where radiation safety is integrated, and to eliminate the licence amendment needed to add authorised users for diagnostic work, at an estimated $39.1 million of net savings over 2027-2031 (Federal Register, 27/07/2026). Licensees would instead “verify and document physician qualifications internally, with NRC or Agreement State oversight occurring primarily through inspections” (American College of Radiology, 23/07/2026).

The demand curve behind it is steep and the delivery curve is not. Modelling with the European Commission's Joint Research Centre puts the EU-27 pool eligible for radioligand therapy at 11,000 to 13,000 in 2025 and roughly 130,000 to 180,000 by 2035, and warns that uptake “may overwhelm available treatment capacity, even in countries with well-developed nuclear medicine infrastructure” (The Lancet Regional Health - Europe, 04/06/2026). Its own utilisation inputs show the gap already: 56.7 eligible per million in high-income countries against 14.2 per million treated with 177Lu-PSMA and 0.3 with 225Ac-PSMA.

Who can actually deliver is narrower still. Roughly 2,586 sites worldwide were treating patients with radiopharmaceutical therapy as of May 2025, and the reviewers name trained nuclear medicine, radiochemistry and manufacturing staff as the practical constraint (Journal of Nuclear Medicine, 01/09/2026). Between 70% and 80% of global nuclear medicine procedures happen in four regions, with 10 to 40 PET scanners per million people in high-income countries against fewer than 1 in many low-income ones (World Journal of Nuclear Medicine, 15/06/2026).

Eligible, treated, and the pool that arrives by 2035

PER MILLION PEOPLE, HIGH-INCOME COUNTRIES 0 20 40 55 Eligible, PSMA-targeting 56.7 Treated, 177Lu-PSMA 14.2 Treated, 225Ac-PSMA 0.3 EU-27 PATIENTS ELIGIBLE FOR RADIOLIGAND THERAPY, MODELLED 0 50,000 100,000 150,000 Eligible in 2025 11,000 to 13,000 EU-4 treated, 2030 17,000 to 35,000 Eligible in 2035 130,000 to 180,000

Source: The Lancet Regional Health - Europe modelling study with the European Commission Joint Research Centre (4 June 2026). The modelling was funded by Novartis, the incumbent with the largest commercial interest in radioligand capacity.

Disruption Pathway

Stage one is rulemaking and runs through 2027. The NRC's comment period closed on 10 September (Federal Register, 27/07/2026), Medicare's companion payment proposal for CY 2027 was published on 7 July (Federal Register, 07/07/2026), and neither is final. Stage two is adoption from 2027 to 2029, as the Agreement States that regulate most medical licensees decide whether to follow, and licensees begin approving authorised users on their own paperwork. Stage three is the test: whether treated volumes actually rise, and what happens the first time an adverse event lands on a physician qualified by the residency pathway rather than by counted hours.

Stress concentrates in three places. The first is the estate itself, because Medicare prices the dose and not the room: the proposed CY 2027 diagnostic radiopharmaceutical packaging threshold is $665 per day, up from $655 (Federal Register, 07/07/2026), while shielded rooms, hot labs and waste handling sit on the hospital's capital account. The second is workforce, though the evidence cuts both ways: at one of Europe's largest theranostics centres recruitment has improved to the point that “we are receiving strong applications and can be selective” (AuntMinnieEurope, 01/09/2026). The third is liability, since internal verification puts the qualification decision on the licensee. Two adaptations follow. Networks centralise therapy into hub sites with contracted staffing. Manufacturers move upstream into infrastructure, making supply contracts and compliance “integral to valuation” (Journal of Nuclear Medicine, 01/09/2026).

Why This Matters Now

This lands on health-system boards planning oncology capital, on pharmaceutical commercial leadership modelling a launch, on payers setting coverage, and on investors pricing radiopharmaceutical assets. The decision architecture that needs revising forecasts from eligible-patient pools and treats radiation safety as a facilities matter. Realised volume is bounded instead by licensed rooms, hot-lab throughput and authorised-user headcount, and the last of those is now set by a nuclear regulator rewriting a qualification rule. Developers should re-anchor peak-sales models on site activation rather than eligibility, and health systems should decide who carries the liability when a licensee approves an authorised user without a licence amendment. Taken together, the sources suggest the credible forecasts will be those built on the delivery estate, not on the addressable population.

Decision-action posture for this signal: Prepare — both instruments are proposals with closed comment periods rather than settled rules, and the Agreement States have yet to decide, so capacity and liability positions should be built against the final rule and the first state adoptions rather than committed against a standard that may still change.

Counter-Argument

The strongest objection is that the ceiling is a financing question with a short payback, and that the regulator's own record does not support a capacity rationale. A physician network puts a basic community programme at “approximately $250,000 for a small, well-designed setup” recoverable quickly at “margins around 14% at Medicare rates” (American Oncology Network, 23/06/2026). The NRC itself records that in March 2016 its advisory committee “found no evidence that the requirement adversely affected patient access” (Federal Register, 27/07/2026). On that reading this is burden reduction, not a capacity fix.

That may be right about the motive and still leave the consequence intact. Whether or not an authorised-user shortage is measurable, the rule moves qualification assurance from prior approval to inspection, which transfers risk to the licensee regardless. And a quarter of a million dollars per site does not scale to a pool modelled at 130,000 to 180,000 patients by 2035.

Implications

This is a durable change rather than a cyclical one, because it moves who decides qualification rather than how much of anything is produced. Once a licensee approves its own authorised users, the approval does not return to the regulator, and the distribution of capacity it governs is already extreme: 70% to 80% of global nuclear medicine procedures sit in four regions (World Journal of Nuclear Medicine, 15/06/2026), against an EU-27 eligible pool modelled to reach 130,000 to 180,000 by 2035 (The Lancet Regional Health - Europe, 04/06/2026). The inflection window runs from the final rule to the first Agreement State adoptions. Hub networks and manufacturers who own infrastructure gain; single-site community programmes and thinly equipped systems do not.

Early Indicators to Monitor

Disconfirming Signals

Strategic Questions

Keywords

Radioligand therapy; radiopharmaceutical therapy; theranostics; authorised user; Nuclear Regulatory Commission; 10 CFR Part 35; nuclear medicine workforce; shielded infusion capacity; hot lab; Medicare outpatient payment; diagnostic radiopharmaceutical packaging threshold; lutetium-177

Bibliography

Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.

This Signal Scan is one component of a Shaping Tomorrow intelligence cycle on Health, Life Sciences & Care Systems. Every monitored topic also includes monthly Change Trackers that assess what is materially shifting in momentum, and a quarterly Decision Intelligence briefing that converts the cycle into board-level strategic implications. Cycles may also close with Action Triggers, an end-of-cycle synthesis that reads across the three formats and surfaces patterns no single deliverable carries on its own. Continuous intelligence on this topic is available as a Single-Topic or Multi-Topic programme.

Discuss a Tailored Programme

Prepared by Shaping Tomorrow: 13 September 2026